News|Articles|August 21, 2026

5 Things to Know About the FDA's Peptide Reversal

FDA advisers overrode their own scientists to back 6 peptides for compounding, even as safety data remains thin and gray-market risks persist.

When a reconstituted FDA advisory panel voted in late July to recommend 6 peptides for legal compounding, it was overriding the recommendation of the agency’s own career scientists, who recommended against it due to a lack of human safety data.¹ The clash comes as HHS Secretary Robert F. Kennedy Jr is moving to reclassify 14 of the 19 restricted peptides back to legal status. However, almost none of these compounds have FDA-approved indications, and with little regulation in place, gray-market vials remain the default source for millions of Americans.

Here are 5 things stakeholders should know about the debate over establishing legitimate peptide regulations.

1. Political Reclassification Changed the Rules

Kennedy announced on February 27, 2026, that approximately 14 of the 19 peptides currently on the FDA's Category 2 restricted compounding list would be moved back to Category 1, which would allow them to be compounded with a prescription. These peptides include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, MOTS-C, and others, while Melanotan II, GHRP-2, GHRP-6, LL-37, and PEG-MGF are expected to remain restricted under Category 2.

The reclassification was expected to take effect by April 23, 2026, ahead of a formal review by the FDA's Pharmacy Compounding Advisory Committee (PCAC) on July 23 to 24, 2026. However, Category 1 status would not constitute FDA approval for these peptides, meaning no validated indications, standardized dosing, or established safety and efficacy data.²

2. The FDA's Own Scientists Pushed Back but the Panel Overruled Them

From July 23 to 24, 2026, the PCAC met at the agency's White Oak campus in Silver Spring, Maryland, to review BPC-157, TB-500, KPV, and MOTS-C for the 503A Bulk Drug Substances List, which governs what compounding pharmacies may legally prepare. The FDA scientists unanimously recommended against adding all 4 peptides, as there is effectively an absence of human clinical data. Notably, BPC-157’s only human clinical evidence is a decades-old, never-published meeting abstract.^3,4

The scientists’ recommendation went to a reconstituted PCAC panel that now includes 8 new members aligned with Kennedy’s approach to deregulation, most of whom have financial ties to businesses that sell or administer peptides.³ The panel voted the opposite way, choosing to recommend 6 of the 7 peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon) for inclusion on the 503A Bulk Drug Substances List. Observers in the room described an audible gasp when the first tally was announced, noting a PCAC panel had rarely, if ever, voted against FDA staff's written recommendation.¹

The FDA must still decide whether to accept the committee's nonbinding recommendation and, if so, proceed through formal notice-and-comment rulemaking, which is a process that can take 12 to 24 months, before compounding pharmacies could legally prepare substances for patients.^1,3

“Patient demand is not necessarily clinical evidence, but you can't pretend that patient demand doesn't exist. It's not a safety strategy either,” said Rachel Strauss, founder and CEO of pharmacy benefit consulting firm PBM Princess, who spoke to The American Journal of Managed Care^® from the payer and drug-access side of the industry rather than as a clinician.

Tech Times noted that this issue matters most for the large and growing number of Americans currently sourcing these peptides through gray-market channels such as wellness clinics, online retailers, and vendors marketing vials as “for research use only.” These products have no quality controls, no sterility guarantees, and no pharmacovigilance oversight. The outlet adds that independent lab testing of these gray-market products has found bacterial contamination severe enough to trigger septic reactions; additionally, there is heavy metal and solvent residue from the manufacturing process and doses in some products that fall well below what was listed on the label.³

3. The Science Gap Behind the Politics

BPC-157, the most popular peptide in the group, is derived from a compound found in human gastric juice. This peptide’s supporting research is based primarily on animal studies, most produced by a single Croatian group led by Predrag Sikiric that has published on the peptide since 1992 and holds undisclosed patents and company ties connected to it. In comparison, human data is nearly nonexistent.

“What we need to standardize is [that] patients need to know what's in the vial, whether it's made consistently, and whether the compounding pharmacy making it is following the right protocols. Eventually, hopefully, we'll have enough human data and trials to understand what happens when people actually use it,” Strauss said.

STAT reports that a University of Utah medical resident who reviewed the available literature concluded BPC-157 should not be used by humans, highlighting the lack of adequate human safety data. That resident physician told the outlet the field has “cured cancer in mice plenty of times” without ever replicating that success in people.

That evidence gap hasn't slowed the market. Wellness entrepreneur Gary Brecka, a podcaster aligned with the Make America Healthy Again movement, sells a BPC-157 nasal spray blend for $375, with a one-month supply of patches running $575 on his own website, despite the products having no approved indication, standardized dosing, or established safety profile.⁵

4. Enforcement Is Now a 50-State Patchwork, Not Just an FDA Problem

While federal regulators debate reclassification, states have taken different paths. Florida, Texas, Nevada, and Arizona remain permissive, with high concentrations of peptide clinics and few added restrictions beyond federal rules. New York, California, Massachusetts, Connecticut, Alabama, and Louisiana have moved in the opposite direction.

Connecticut forced a peptide seller to shut down in 2025 and issued a statewide notice to clinics on GLP-1 compounding. Alabama's attorney general obtained a restraining order against an unapproved peptide seller in November 2025. New York now requires facility inspections and compliance documentation and, as of April 2025, bars the sale of peptide products marketed for muscle building or weight loss to anyone under 18.

The state-level response isn't limited to a handful of cases. More than 40 state attorneys general sent a coordinated letter to the FDA in 2025 raising contamination and safety concerns, a sign that multistate enforcement is increasingly filling the space left by federal inaction.⁶

5. The Peptide Fight Is Colliding with Mainstream GLP-1s

The regulatory battle over peptides isn't confined to wellness clinics and gray-market vials. On February 6, 2026, the FDA separately announced it would restrict the active pharmaceutical ingredients used in mass-marketed compounded semaglutide and tirzepatide and crack down on marketing that describes those compounded products as “generic” or “equivalent” to FDA-approved versions.

The FDA highlighted that compounding should be limited to cases of patient-specific medical necessity or drug shortages, not mass production. Former FDA Commissioner Martin A. Makary, MD, MPH, made clear the agency was prepared to enforce that line, stating that entities engaged in manufacturing, distributing, or marketing unapproved compounded GLP-1 products “should be aware that failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.”^7,8

What Is Next for Peptides?

Whether the FDA formally acts on the PCAC's recommendation or moves to override it under political pressure will determine if the 6 peptides move onto the Category 1 list or remain suspended in the same regulatory gray zone they currently occupy. It also remains to be seen whether more states follow Connecticut, Alabama, and New York into active enforcement, or whether a federal preemption fight emerges as the patchwork widens. With the FDA already applying ingredient and marketing restrictions to compounded GLP-1s, that parallel track could become the template regulators use for wellness peptides as well. For now, peptides are already being prescribed, sold through gray-market channels, and litigated well ahead of any resolution.

“We shouldn't be recreating another wild, wild west with a pharmacy label on it. The entire point of the FDA getting involved is that we have to put guardrails around something patients are already taking, not something they're just seeking,” Strauss concluded.

References